-
Je něco špatně v tomto záznamu ?
Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis
I. Stojanovic, M. Dimitrijevic, M. Vives-Pi, MJ. Mansilla, I. Pujol-Autonell, S. Rodríguez-Fernandez, L. Palova-Jelínkova, DP. Funda, A. Gruden-Movsesijan, L. Sofronic-Milosavljevic, CMU. Hilkens, E. Martinez-Caceres, D. Miljkovic,
Current pharmaceutical design.
2017 ;
23 (18) :
2623-2643.
Jazyk angličtina Země Spojené arabské emiráty
Typ dokumentu časopisecké články, přehledy
Perzistentní odkaz
https://www.medvik.cz/link/bmc18025157
- MeSH
- autoimunita účinky léků imunologie MeSH
- buněčná a tkáňová terapie metody MeSH
- diabetes mellitus 1. typu imunologie terapie MeSH
- imunologická tolerance účinky léků imunologie MeSH
- imunosupresiva aplikace a dávkování MeSH
- lidé MeSH
- modely nemocí na zvířatech * MeSH
- organické látky aplikace a dávkování MeSH
- regulační T-lymfocyty účinky léků imunologie MeSH
- revmatoidní artritida imunologie terapie MeSH
- roztroušená skleróza imunologie terapie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18025157
- 003
- CZ-PrNML
- 005
- 20180712092605.0
- 007
- ta
- 008
- 180709s2017 ts f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1381612823666170214120708 $2 doi
- 035 __
- $a (PubMed)28201972
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ts
- 100 1_
- $a Stojanovic, Ivana $u Department of Immunology, Institute for Biological Research "Sinisa Stankovis", University of Belgrade, Belgrade, Serbia.
- 245 10
- $a Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis / $c I. Stojanovic, M. Dimitrijevic, M. Vives-Pi, MJ. Mansilla, I. Pujol-Autonell, S. Rodríguez-Fernandez, L. Palova-Jelínkova, DP. Funda, A. Gruden-Movsesijan, L. Sofronic-Milosavljevic, CMU. Hilkens, E. Martinez-Caceres, D. Miljkovic,
- 520 9_
- $a Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a revmatoidní artritida $x imunologie $x terapie $7 D001172
- 650 _2
- $a autoimunita $x účinky léků $x imunologie $7 D015551
- 650 _2
- $a buněčná a tkáňová terapie $x metody $7 D064987
- 650 _2
- $a diabetes mellitus 1. typu $x imunologie $x terapie $7 D003922
- 650 12
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunologická tolerance $x účinky léků $x imunologie $7 D007108
- 650 _2
- $a imunosupresiva $x aplikace a dávkování $7 D007166
- 650 _2
- $a roztroušená skleróza $x imunologie $x terapie $7 D009103
- 650 _2
- $a organické látky $x aplikace a dávkování $7 D009930
- 650 _2
- $a regulační T-lymfocyty $x účinky léků $x imunologie $7 D050378
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Dimitrijevic, Mirjana $u Department of Immunology, Institute for Biological Research "Sinisa Stankovis", University of Belgrade, Belgrade, Serbia.
- 700 1_
- $a Vives-Pi, Marta $u Immunology Division, Germans Trias i Pujol University Hospital, Department of Cellular Biology, Physiology, and Immunology, Universitat Autònoma Barcelona, Campus Can Ruti, 08916 Barcelona, Spain.
- 700 1_
- $a Mansilla, Maria Jose $u Immunology Division, Germans Trias i Pujol University Hospital, Department of Cellular Biology, Physiology, and Immunology, Universitat Autònoma Barcelona, Campus Can Ruti, 08916 Barcelona, Spain.
- 700 1_
- $a Pujol-Autonell, Irma $u Immunology Division, Germans Trias i Pujol University Hospital, Department of Cellular Biology, Physiology, and Immunology, Universitat Autònoma Barcelona, Campus Can Ruti, 08916 Barcelona, Spain.
- 700 1_
- $a Rodríguez-Fernandez, Silvia $u Immunology Division, Germans Trias i Pujol University Hospital, Department of Cellular Biology, Physiology, and Immunology, Universitat Autònoma Barcelona, Campus Can Ruti, 08916 Barcelona, Spain.
- 700 1_
- $a Palova-Jelínkova, Lenka $u SOTIO a.s., Prague, Czech Republic.
- 700 1_
- $a Funda, David P $u Department of Immunology and Gnotobiology, Institute of Microbiology of the CAS,v.v.i., Prague, Czech Republic.
- 700 1_
- $a Gruden-Movsesijan, Alisa $u Department for Immunology and Immunoparasitology, Institute for the Application of Nuclear Energy - INEP, University of Belgrade, Belgrade, Serbia.
- 700 1_
- $a Sofronic-Milosavljevic, Ljiljana $u Department for Immunology and Immunoparasitology, Institute for the Application of Nuclear Energy - INEP, University of Belgrade, Belgrade, Serbia.
- 700 1_
- $a Hilkens, Catharien M U $u Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, NE2 4HH, United Kingdom.
- 700 1_
- $a Martinez-Caceres, Eva $u Immunology Division, Germans Trias i Pujol University Hospital, Department of Cellular Biology, Physiology, and Immunology, Universitat Autònoma Barcelona, Campus Can Ruti, 08916 Barcelona, Spain.
- 700 1_
- $a Miljkovic, Djordje $u Institute for Biological Research "Sinisa Stankovic", Department of Immunology, Despota Stefana 142, 11000 Belgrade, Serbia.
- 773 0_
- $w MED00007893 $t Current pharmaceutical design $x 1873-4286 $g Roč. 23, č. 18 (2017), s. 2623-2643
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28201972 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180712092858 $b ABA008
- 999 __
- $a ok $b bmc $g 1317288 $s 1022078
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 23 $c 18 $d 2623-2643 $i 1873-4286 $m Current pharmaceutical design $n Curr Pharm Des $x MED00007893
- LZP __
- $a Pubmed-20180709
